NCT04267926CompletedPhase 1/2
MitoQ for Fatigue in Multiple Sclerosis (MS)
MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 11 Feb 2020
- Start date
- 1 Apr 2020
- Primary completion date
- 15 Oct 2024
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Multiple sclerosis
- NCT number
- NCT04267926
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 45
- From 1 Apr 2020 to the primary completion date, 15 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- treatment with systemic glucocorticoids in the prior six weeks
- significant MS exacerbation in prior 30 days
- previous use of MitoQ or Coenzyme Q10 (CoQ10) within thirty days of screening appointment
Other illness
- other significant health problem that might increase risk of patient experiencing Adverse Events (AEs), e.g.:
- active coronary heart disease
- liver disease
- pulmonary disease
- diabetes mellitus
- any condition which would make the patient in the opinion of the investigator unsuitable for the study
Other
- Beck Depression Inventory (BDI) \>31 or BDI-FS\>10 (severe depression)
- pregnancy or intending to become pregnant or breastfeeding
- unable to complete the self-report forms
- unable to give informed consent
- prisoners
Who the study is looking for
- MS (any clinical subtype) as diagnosed by the 2017 McDonald criteria
- EDSS score of 2 to 8
- complaint of fatigue that has been persistent for at least two months
- Modified Fatigue Impact Scale (MFIS) score of 38 or greater
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| VA Portland Health Care System, Portland, OR Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.